trial

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

NCTId NCT00097942
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 138 (actual)
Sponsored by Forest Laboratories
Primary completion 2005-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
138 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-08
Primary completion
2005-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
memantine HCl

Sponsors

Forest LaboratoriesLead Sponsor

Sites

13 total
National City, United StatesSan Diego, United StatesMiami, United StatesIowa City, United StatesRockville, United StatesSt Louis, United StatesLebanon, United StatesOrangeburg, United StatesButner, United StatesRaleigh, United StatesCincinnati, United StatesIrving, United States

Linked catalysts

1
Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Sc — primary completion2005-09

Facts & assertions

4 sourced
Enrollment
138
Phase
PHASE2
Primary Completion Date
2005-09
Status
COMPLETED
relationships
The graph out of here
drug
memantine HCl
drug
lead_sponsor
Forest Laboratories
company
indication
Schizophrenia
indication
Schizophrenia
indication